Where We Are and Where We Are Headed

TGRx’s business model includes development agreements with companies and government agencies for human and veterinary therapeutics and diagnostics ranging from monoclonal antibodies to cytokines. The company’s strategic plan is to become the manufacturing partner of choice for biotechnology companies producing new therapeutic proteins, as well as to provide a cost-effective alternative to biotechnology firms producing established products. This strategic manufacturing position provides TGRx the ability to enter markets for proteins used in therapeutics, diagnostics, reagents and in industrial settings currently too expensive to produce by conventional methods. The speed at which the company can enter these markets is quite remarkable. We now have scientific validation of the core technologies in avians (quail and chicken). The company’s initial goal is to make an early and significant market entry in the area of generic biologicals.

The rate of protein drug development has been rapidly increasing over the past several years with 500 or more protein drugs currently in various stages of development and regulatory approval. Industry analysts are unanimous in their conclusion: a shortfall exists in the manufacturing capacity for the drugs currently approved for sale. With more drugs gaining regulatory approval, analysts predict a slowing of industry growth unless a new technology for the cost-effective manufacturing of therapeutic proteins is developed. Many of the new generation of protein drugs require significantly larger and more frequent doses, which magnifies the production shortfall. TGRx believes its technology provides the solution to this production shortfall and that the introduction of its technology in the marketplace could not come at a better time.

The lower cost of production will benefit the biotech sector and the general public. Biopharmaceutical companies will have the ability to increase market penetration and reduce capital expenditures for manufacturing facilities, while maintaining their profit margins. The public benefits from the availability of more therapeutics at a lower cost. In short, the company’s technology provides a basis for the industry to maintain growth and increase the development of additional therapies. The biotech industry is facing for the first time true competition in the marketplace as new therapeutics are being approved. This results in multiple therapies for single indications (there are five drugs for rheumatoid arthritis, for example).  TGRx's alternative production methods provide the industry with solutions to the manufacturing shortage and the need for lower cost of production. The development of TGRx's proprietary technology comes at a crucial time for the continued growth and advancement of the biotech industry.  

For more information on business opportunities with TGRx, please contact us at bizdev@tgrx.com